Clinical Trials in China / NCT07862010
Recruiting
Early Phase 1
Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
NCT07862010 · tracked via the Priya Life Science China tracker
Condition(s) studied
B-Cell Non-Hodgkin LymphomaB-Cell Acute Lymphoblastic Leukemia
Investigational drug(s) / intervention(s)
GI001
GI001: GI001 is an in vivo CD19-targeted CAR-T therapy. It is a lentiviral vector-based product using a third-generation self-inactivating lentiviral vector system with a five-plasmid packaging design. GI001 is administered by intravenous injection and delivers the CD19 CAR gene directly into the patient, reprogramming the patient's own T cells in situ to express CD19 CAR without ex vivo cell manufacturing. No lymphodepleting conditioning is required, and a single injection is given. GI001 is supplied as a colorless to slightly opaque liquid, 1 mL per vial, stored at -70 +/- 10 degrees C. Infusion duration does not exceed 2 hours. Dose levels evaluated in this study are 3.5x10\^8 TU, 7.0x10\^8 TU and 1.0x10\^9 TU (TU = transducing units). Recommended premedication is intramuscular promethazine 25 mg or diphenhydramine 20 mg given 15-30 minutes before infusion. Dose modification is not permitted (a +/-20% dose range is acceptable).
Study summary
This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) and B-cell Acute Lymphoblastic Leukemia (R/R B-ALL).
GI001 is an exploratory, in vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD19 antigen. Unlike traditional CAR-T cell therapies that require extensive in vitro cell manufacturing, GI001 is administered directly to the patient via intravenous infusion, aiming to generate CAR-T cells directly within the patient's body.
The study consists of two main phases:
* Dose-Escalation Phase: This phase will evaluate four ascending dose levels to assess safety, identify any Dose-Limiting Toxicities (DLTs), determine the Maximum Tolerated Dose (MTD), and establish the Recommended Dose for Expansion (RDE). It utilizes an accelerated titration design for the initial doses, followed by a standard "3+3" dose-escalation design.
* Dose-Expansion Phase ： Once the RDE is identified, additional patients will be enrolled to further evaluate the safety, clinical efficacy, pharmacokinetics, and pharmacodynamics of GI001 at the selected dose(s).
The primary focus of the study is to continuously monitor adverse events and evaluate the overall safety profile. Secondary objectives include assessing clinical response rates (such as Objective Response Rate and Complete Response Rate), survival outcomes, and the expansion levels of CAR-T cells in the peripheral blood.
Eligibility
Inclusion Criteria:
1\. Age 18 to 75 years, inclusive.
* 2\. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) or R/R B-cell acute lymphoblastic leukemia (B-ALL):
* 2.1 CD19-positive R/R B-NHL meeting the following:
* Histopathologic diagnosis of indolent NHL (iNHL), including but not limited to follicular lymphoma (FL) and marginal zone lymphoma (MZL), or small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL); or aggressive B-cell lymphoma, including but not limited to diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-cell/histiocyte-rich large B-cell lymphoma (TCRBCL).
* Refractory disease defined as: (a) best response of progressive disease (PD) to first-line standard therapy, or stable disease (SD) after at least 4 cycles of first-line therapy with SD duration not exceeding 6 months after the last treatment; or (b) no response to second-line or later therapy, including best response of PD to the most recent therapy, or SD after at least 2 cycles of the most recent therapy with SD duration not exceeding 6 months after the last treatment; or (c) disease progression within 12 months after autologous hematopoietic stem cell transplantation (ASCT) or biopsy-confirmed relapse, or no remission or relapse (SD or PD) after salvage therapy following ASCT.
* Relapse defined as PD after achieving a response (partial response \[PR\] or complete response \[CR\]) to adequate prior therapy.
* Note: participants must have received adequate prior therapy; participants with CD20-positive disease must have failed or relapsed after anti-CD20 monoclonal antibody therapy.
* 2.2 CD19-positive R/R B-ALL meeting the following:
* Relapse defined as: (a) hematologic relapse: reappearance of blasts (\>=5%) in peripheral blood or bone marrow, or extramedullary disease, in a participant who had achieved CR; or (b) molecular relapse: reappearance of measurable residual disease (MRD) positivity after hematologic CR (HCR) and CR MRD negativity, with an increase in MRD level of \>=1 log between two positive specimens.
* Refractory disease defined as: (a) failure to achieve CR after at least 2 cycles of standard chemotherapy, or late relapse (\>=12 months) after CR with failure to achieve CR after at least 1 additional cycle; or (b) relapse after hematopoietic stem cell transplantation, or failure to achieve remission with the last therapy in participants receiving salvage therapy after HSCT; or (c) failure to achieve CR or relapse after at least 2 tyrosine kinase inhibitors (TKIs) (participants with TKI-resistance mutations such as T315I/A, V299L, F317L/V/I/C, G250E, Y253H, E255K/V, or F359V/C/I are not required to have received at least 2 TKIs), or intolerance to or contraindication for TKIs, in Philadelphia chromosome-positive (Ph+) B-ALL.
* 2.3 Participants who are not eligible for stem cell transplantation, or whose medical records document refusal of other available therapies, may also be enrolled.
* 3\. CD19 expression positivity confirmed by immunohistochemistry (IHC) or flow cytometry (FACS) on tumor specimen, bone marrow, or peripheral blood at screening.
* 4\. Measurable disease per Lugano 2014 criteria for B-NHL participants (nodal lesion LDi \> 1.5 cm, extranodal lesion LDi \> 1.0 cm); bone marrow blasts and immature lymphocytes \>=5% for B-ALL participants at screening.
* 5\. ECOG performance status 0 to 2.
* 6\. Expected survival \>=12 weeks.
* 7\. Adequate organ function meeting all of the following laboratory results before enrollment:
* Hematology: bone marrow reserve for R/R B-NHL participants must meet: absolute neutrophil count (ANC) \> 0.5 x 10\^9/L (no short-acting G-CSF within 7 days and no long-acting G-CSF within 14 days before testing); absolute lymphocyte count (ALC) \>= 0.5 x 10\^9/L; platelet count \>= 30 x 10\^9/L (no platelet transfusion within 7 days before testing); hemoglobin \>= 80 g/L (no red blood cell transfusion within 7 days before testing; recombinant erythropoietin permitted). All participants (B-NHL and B-ALL) require absolute CD3+ T cell count \>= 150/uL.
* Hepatic: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<= 3 x upper limit of normal (ULN); total serum bilirubin \<= 2 x ULN.
* Renal: creatinine clearance (CrCl) \>= 60 mL/min (Cockcroft-Gault formula).
* Coagulation: fibrinogen \>= 1.0 g/L; activated partial thromboplastin time \<= 1.5 x ULN; prothrombin time (PT) \<= 1.5 x ULN.
* Cardiac: left ventricular ejection fraction (LVEF) \>= 55%; oxygen saturation \> 91%.
* 8\. Therapeutic-dose steroids must be discontinued 72 hours before GI001 infusion (physiologic replacement-dose steroids are permitted).
* 9\. CNS disease prophylaxis (e.g., intrathecal methotrexate) must be discontinued 1 week before GI001 infusion.
* 10\. Participants and their partners agree to use effective barrier or pharmacologic contraception (excluding calendar/rhythm methods) from the time of informed consent through 1 year after GI001 administration.
* 11\. Written informed consent approved by the ethics committee must be obtained before initiating any screening procedures.
Exclusion Criteria:
1\. Prior antitumor therapy as follows (except agents proven to enhance CAR-T cell efficacy or not to affect CAR-T cells, after an appropriate washout period):
* Cytotoxic chemotherapy within 2 weeks before dosing.
* Small molecule targeted therapy within 2 weeks before dosing.
* Antibody therapy within 3 weeks before dosing.
* Pegylated asparaginase within 4 weeks before dosing.
* Immunosuppressive therapy within 4 weeks before dosing or requirement for long-term immunosuppression.
* Radiotherapy within 4 weeks before dosing.
* Bendamustine within 6 months before dosing.
* Prior treatment with any gene therapy product, including CAR-T therapy (except participants with no in vivo CAR-T, normal T cell count and function, and CD19-positive tumor).
* Prior treatment with any anti-CD19/anti-CD3 therapy or any other anti-CD19 therapy (except participants with normal T cell count and function and CD19-positive tumor).
* Other investigational drugs or other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) before dosing.
* 2\. Other malignancy within 2 years before screening, excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical prostatectomy, ductal carcinoma in situ of the breast after radical surgery, and papillary thyroid carcinoma after radical treatment.
* 3\. History of solid organ transplantation.
* 4\. Use of immunomodulatory agents within 2 weeks before dosing, or likely use during the study, including but not limited to thalidomide, lenalidomide, and pomalidomide.
* 5\. Requirement for long-term therapeutic-dose corticosteroids (defined as prednisone or equivalent \> 15 mg/day); physiologic replacement, topical, and inhaled use are permitted.
* 6\. Prior or current CNS involvement or suspected CNS involvement: leukemia or lymphoma cells detected in cerebrospinal fluid (CSF); or imaging findings of mass, thickening, or enhancement in brain parenchyma, meninges, cranial nerves, or spinal cord supporting a diagnosis of CNS involvement; or neurologic signs or symptoms with abnormal CSF findings suggestive of CNS involvement.
* 7\. Hypertension not controllable with medication.
* 8\. Severe cardiac disease, including but not limited to: myocardial infarction within 6 months before screening; coronary artery bypass grafting or coronary stent placement within 6 months before screening; unstable angina; congestive heart failure (New York Heart Association class \>= III); severe arrhythmia; history of severe non-ischemic cardiomyopathy.
* 9\. Unstable systemic disease as judged by the investigator, including but not limited to severe hepatic, renal, or metabolic disease requiring medication.
* 10\. Uncontrolled active bacterial, fungal, viral, or other infection, or infection requiring intravenous anti-infective therapy (uncontrolled infection defined as persistent infection-related signs or symptoms without improvement after appropriate anti-infective therapy).
* 11\. Stroke, seizure, or other CNS disease unsuitable for this study within 6 months before screening; uncontrolled psychiatric disorder; or any medical or psychiatric history that in the investigator's judgment may increase the risk of study participation or dosing, or may interfere with study results.
* 12\. History of deep vein thrombosis or pulmonary embolism within 6 months before screening.
* 13\. Live vaccine within 6 weeks before screening.
* 14\. Major surgery within 2 weeks before screening, or planned surgery within 2 weeks after dosing (excluding surgery under local anesthesia).
* 15\. Pregnant or breastfeeding women, or women planning pregnancy during or after treatment.
* 16\. Non-hematologic toxicity from prior therapy not resolved to baseline or \<= grade 2 (excluding alopecia, fatigue, and peripheral neuropathy).
* 17\. Prior treatment with a therapeutic pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) or Nipah virus.
* 18\. Positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with hepatitis B virus DNA (HBV-DNA) above the lower limit of detection; positive hepatitis C virus (HCV) antibody with HCV-RNA above the lower limit of detection; positive human immunodeficiency virus (HIV) antibody; or positive syphilis serology.
* 19\. Isolated extramedullary relapse of B-ALL.
* 20\. Hypersensitivity to the investigational drug or its excipients, or to tocilizumab.
* 21\. Primary immunodeficiency.
* 22\. Planned hematopoietic stem cell transplantation within 28 days after GI001 infusion.
* 23\. Any other condition that in the investigator's judgment makes the participant unsuitable for enrollment.
Primary outcome measure(s)
- Incidence and severity of adverse events (AEs) — From baseline through 2 years after GI001 administration
Incidence, severity, seriousness, and relationship to GI001 of treatment-emergent adverse events and serious adverse events. Severity graded per NCI CTCAE v6.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) graded per ASTCT 2019 consensus criteria; immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) graded per ASTCT 2023 criteria. - Change from baseline in body temperature — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in body temperature, measured in degrees Celsius, at each scheduled post-dose assessment. - Percentage of participants with dose-limiting toxicities (DLTs) — From GI001 administration through 28 days after administration
Percentage of participants in the DLT analysis set who experience at least one protocol-defined DLT within 28 days after GI001 administration. The analysis set includes participants who complete DLT assessment or experience a DLT during the assessment period. DLTs are treatment-related toxicities defined in Protocol Section 4.1.4, including qualifying cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infusion-related hypersensitivity, non-hematologic toxicities, neutropenia with severe infection, thrombocytopenia with qualifying bleeding, and grade 5 toxicity. Protocol-specified severity thresholds, recovery criteria, and exclusions apply. The number and percentage of participants with DLTs will be summarized. - Maximum tolerated dose (MTD) — From GI001 administration through 28 days after administration for each participant in the dose-escalation phase
The highest GI001 dose level, expressed in transducing units (TU), at which no more than 1 of 6 evaluable participants experiences a protocol-defined dose-limiting toxicity (DLT) during the 28-day observation period after administration. If only 3 participants have been enrolled at the candidate MTD, 3 additional participants are enrolled for confirmation. The MTD is determined from the dose-escalation cohort data. - Recommended dose for expansion (RDE) — From GI001 administration through 90 days after administration for each participant in the dose-escalation phase
GI001 dose level(s), expressed in transducing units (TU), selected for expansion by the Safety Review Committee based on available safety, tolerability, preliminary efficacy, pharmacokinetic, pharmacodynamic, and immunogenicity data from the dose-escalation phase. - Change from baseline in systolic blood pressure — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg), at each scheduled post-dose assessment. - Change from baseline in pulse rate — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in pulse rate, measured in beats per minute, at each scheduled post-dose assessment. - Change from baseline in respiratory rate — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in respiratory rate, measured in breaths per minute, at each scheduled post-dose assessment. - Change from baseline in ECOG performance status score — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status score at each scheduled post-dose assessment. Scores range from 0 (fully active) to 5 (death), with higher scores indicating worse performance status. - Change from baseline in heart rate measured by 12-lead ECG — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in heart rate, measured in beats per minute by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged. - Change from baseline in PR interval measured by 12-lead ECG — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in PR interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged. - Change from baseline in R-R interval measured by 12-lead ECG — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in R-R interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged. - Change from baseline in diastolic blood pressure — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg), at each scheduled post-dose assessment. - Change from baseline in QRS duration measured by 12-lead ECG — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in QRS duration, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged. - Change from baseline in QT interval measured by 12-lead ECG — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in QT interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged. - Change from baseline in QTcF interval measured by 12-lead ECG — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in QT interval corrected for heart rate using the Fridericia formula (QTcF), measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. QTcF = QT / (RR in seconds)\^(1/3). After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged. - Number of participants by change from baseline in physical examination findings — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Physical examination findings are classified as normal or abnormal by the investigator. The number of participants in each baseline-to-post-dose category (normal to normal, normal to abnormal, abnormal to normal, or abnormal to abnormal) will be summarized by examined body system and scheduled visit. Examinations cover the head, eyes, ears, nose, throat, neck, heart, chest including lungs, abdomen, extremities, skin, lymph nodes, nervous system, and general condition. Post-dose examinations may focus on clinically indicated organs and systems, as specified in the protocol. - Number of participants by change from baseline in overall 12-lead ECG assessment — Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
The overall 12-lead electrocardiogram (ECG) assessment is classified as normal or abnormal by the investigator. The number of participants in each baseline-to-post-dose category (normal to normal, normal to abnormal, abnormal to normal, or abnormal to abnormal) will be summarized at each scheduled post-dose assessment. This outcome describes the overall ECG interpretation; quantitative ECG parameters are reported separately. - Change from baseline in red blood cell count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in red blood cell count, measured in 10\^12/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in hemoglobin concentration — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in hemoglobin concentration, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in hematocrit — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in hematocrit, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points. - Change from baseline in white blood cell count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in white blood cell count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in platelet count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in platelet count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in absolute neutrophil count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute neutrophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in absolute lymphocyte count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute lymphocyte count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in absolute monocyte count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute monocyte count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in absolute eosinophil count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute eosinophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in absolute basophil count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute basophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in neutrophil percentage — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in neutrophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points. - Change from baseline in lymphocyte percentage — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in lymphocyte percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points. - Change from baseline in monocyte percentage — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in monocyte percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points. - Change from baseline in eosinophil percentage — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in eosinophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points. - Change from baseline in basophil percentage — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in basophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points. - Change from baseline in alanine aminotransferase (ALT) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in alanine aminotransferase (ALT), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in aspartate aminotransferase (AST) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in aspartate aminotransferase (AST), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in gamma-glutamyl transferase (GGT) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in gamma-glutamyl transferase (GGT), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in alkaline phosphatase (ALP) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in alkaline phosphatase (ALP), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in lactate dehydrogenase (LDH) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in lactate dehydrogenase (LDH), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in creatine kinase (CK) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in creatine kinase (CK), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in creatine kinase-MB (CK-MB) activity — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in creatine kinase-MB (CK-MB) activity, measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in total bilirubin — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in total bilirubin, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in direct bilirubin — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in direct bilirubin, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in creatinine — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in creatinine, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in uric acid — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in uric acid, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in glucose — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in glucose, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in urea — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urea, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in potassium — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in potassium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in sodium — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in sodium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in chloride — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in chloride, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in inorganic phosphorus — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in inorganic phosphorus, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in total protein — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in total protein, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in albumin — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in albumin, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in globulin — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in globulin, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in albumin-to-globulin ratio — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in albumin-to-globulin ratio, measured in unitless, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in prothrombin time (PT) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in prothrombin time (PT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in activated partial thromboplastin time (APTT) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in thrombin time (TT) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in thrombin time (TT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in fibrinogen — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in fibrinogen, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in international normalized ratio (INR) — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in international normalized ratio (INR), measured in unitless, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in urine pH — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urine pH, measured in pH units, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in urine white blood cell count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urine white blood cell count, measured in cells/microliter, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in urine red blood cell count — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urine red blood cell count, measured in cells/microliter, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in magnesium — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in magnesium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in troponin concentration measured by chemiluminescence immunoassay — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in troponin concentration measured by chemiluminescence immunoassay, measured in ng/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Change from baseline in D-dimer — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in D-dimer, measured in mg/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. - Number of participants by change from baseline in urine protein category — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants in each baseline-to-post-dose category of urine protein at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall. - Number of participants by change from baseline in urine glucose category — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants in each baseline-to-post-dose category of urine glucose at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall. - Number of participants by change from baseline in urine ketones category — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants in each baseline-to-post-dose category of urine ketones at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall. - Number of participants by change from baseline in urine urobilinogen category — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants in each baseline-to-post-dose category of urine urobilinogen at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall. - Number of participants by change from baseline in urine leukocyte esterase category — Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants in each baseline-to-post-dose category of urine leukocyte esterase at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The 920th Hospital of Joint Logistics Support Force, PLA | Yunnan | Kunming | Recruiting |
More Hematology department of the 920th hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07862010 on ClinicalTrials.gov ↗ ← All trials in China